Bicycle Therapeutics plc
NASDAQ:BCYCBiotechnology
-$0.06 today
- Market cap
- $217.99M
- Beta
- 1.54
- P/E (TTM)
- -1.3
- EPS (TTM)
- -$3.14
Volume 0.57M
Average 0.49M
BCYC Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Bicycle Therapeutics plcNASDAQ: BCYC
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation declines year over year
Q1 FY2026 stock-based compensation of $6.93M fell 27.9% year over year, ahead of the -107.0% change in trailing-twelve-month stock-based compensation. Over 3 fiscal years it compounded at +13.8% a year.
Context
- Stock-based compensation amounted to 54.4% of revenue in FY2025, down 53.6 pp from a year earlier.
- Stock-based compensation increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -27.9% holds above the trailing-twelve-month pace of -107.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 39.46M USD
- Year-over-year change
- +3.6%
- 4-year CAGR
- +34.4%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 39.46M | +3.6% |
| FY2024 | 2024-12-31 | 38.08M | +17.3% |
| FY2023 | 2023-12-31 | 32.48M | +21.3% |
| FY2022 | 2022-12-31 | 26.78M | +121.6% |
| FY2021 | 2021-12-31 | 12.08M | — |
Stock-Based Compensation vs competitors
How BCYC compares with its peers on the latest reported figures
- BCYC's LTM Mar 2026 stock-based compensation of $2.68M is the smallest of the 10 companies compared; the peer median is $12.63M.
- Its year-over-year change of -107.0% is the lowest of 9, against a peer median of -1.1%.
- Stock-based compensation amounts to 4.2% of revenue for BCYC, versus a peer median of 20.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $33.61M | -24.5% | +6.3% | 58.0% | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $27.96M | -33.3% | +53.3% | — |
| LTM Mar 2026 | $19.48M | -28.2% | +8.7% | 22.1% | |
| LTM Mar 2026 | $13.16M | -4.7% | -2.3% | — | |
| LTM Mar 2026 | $12.63M | +26.4% | -48.5% | 16.0% | |
| LTM Mar 2026 | $12.55M | +2.5% | +2.8% | 18.0% | |
| LTM Mar 2026 | $10.93M | +20.5% | +16.2% | — | |
| LTM Mar 2026 | $5.74M | +13.3% | — | 58.0% | |
| LTM Dec 2025 | $5.38M | — | — | 4.6% | |
| LTM Mar 2026 | $2.68M | -107.0% | +13.8% | 4.2% | |
| Peer median (excluding BCYC) | $12.63M | -1.1% | +6.3% | 20.1% | |
Competitors are the stored peer set for BCYC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (66.82M) | (112.72M) | (180.66M) | (169.03M) | (218.96M) |
| Depreciation & Amortization | 1.41M | 3.69M | 6.55M | 7.17M | 6.42M |
| Deferred Income Tax | (1.67M) | (4.98M) | 3.31M | (5.23M) | (850K) |
| Stock-Based Compensation | 12.08M | 26.78M | 32.48M | 38.08M | 39.46M |
| Change in Working Capital | 38.07M | 672K | 76.66M | (33.46M) | (75.75M) |
| Accounts Receivables | 4.54M | (11.35M) | (1.2M) | (11.95M) | 2.89M |
| Inventory | (4.79M) | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.2M | 2.56M | 8M | 3.1M | (6.87M) |
| Other Working Capital | 37.12M | 9.46M | 69.86M | (24.61M) | (71.77M) |
| Other Non-Cash Items | 2.14M | 442K | 1.04M | (2.26M) | 0 |
| Operating Cash Flow | (14.79M) | (86.11M) | (60.63M) | (164.72M) | (249.68M) |
| Capital Expenditures | (2.03M) | (18.99M) | (2.93M) | (1.24M) | (2.36M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 5.49K |
| Investing Cash Flow | (2.03M) | (18.99M) | (2.93M) | (1.24M) | (2.35M) |
| Debt Repayment | 15M | 0 | 0 | (31.91M) | 0 |
| Common Stock Issued | 298.54M | 5.7M | 249.35M | 544.13M | 37.09K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 7.18M | 989K | 682K | 7.53M | (168.09K) |
| Financing Cash Flow | 320.73M | 6.69M | 250.03M | 519.75M | (131K) |
| Effect of Forex Changes | (1.21M) | (1.12M) | 1.35M | (694K) | 804K |
| Net Change in Cash | 302.69M | (99.53M) | 187.82M | 353.1M | (251.35M) |
| Free Cash Flow | (16.82M) | (105.1M) | (63.56M) | (165.96M) | (252.61M) |
Bicycle Therapeutics plc
NASDAQ:BCYC
Intrinsic Alpha fair value
Locked
Current Price
$3.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.